|
|
 |
|
Viewing report
|
|
|
|
Progenics Pharmaceuticals, Inc.
Datamonitor, Sep 2008, Pages: 25
The Progenics Pharmaceuticals, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Progenics Pharmaceuticals (Progenics) is a biopharmaceutical company engaged in the development and commercialization of innovative therapeutic products to meet the medical needs in the areas of gastroenterology, virology and oncology. Progenics, in collaboration with Wyeth, is developing Relistor (methylnaltrexone bromide) for the treatment of opioid-induced side effects. The subcutaneous form of Relistor is approved for use in the US, Canada and European Union member states as well as in Iceland, Norway and Liechtenstein. Progenics is headquartered in Tarrytown, New York and employed 245 people as of December 2007. The company recorded revenues of $76 million during the financial year (FY) ended December 2007, an increase of 8.2% over FY2006. The increase was primarily attributable to increased research revenues from Wyeth related to the development of subcutaneous, intravenous and oral formulations of methylnaltrexone. The operating loss of the company was $51 million during FY2007, as compared to an operating loss of $29 million in FY2006. The net loss was $44 million in FY2007, as compared to a net loss of $22 million in FY2006.
Scope of the Report
- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement
Reasons to Purchase
- Support sales activities by understanding your customers’ businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors’ business structure, strategy and prospects
- Obtain the most up to date company information available
Customers who bought this item also bought
Progenics Pharmaceuticals, Inc. - SWOT Analysis
Premium Company Profile Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
Analysis of Progenics Pharmaceuticals
RELISTOR (Methylnaltrexone Bromide) Approval Call - Progenics Pharmaceuticals, Inc., - Earnings Transcript
Progenics Pharmaceuticals, Inc.
Wyeth - SWOT Analysis
Progenics Pharmaceuticals, Inc. and Wyeth Pharmaceuticals License Agreement Call - Progenics Pharmaceuticals, Inc., - Earnings Transcript
Amylin Pharmaceuticals, Inc. - SWOT Analysis
Idenix Pharmaceuticals, Inc.
Progenics Pharmaceuticals Inc-Therapeutic Competitors
Isis Pharmaceuticals, Inc. - SWOT Analysis
|
|
|
|
